Benzinga | Nov 9, 2020 08:08AM EST

Phio Announces Positive In Vivo Data On Combination PD-1 And TIGIT Checkpoint Blockade With INTASYL In A Single Therapeutic For Cancer Treatment

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL(tm)) therapeutic platform, today announced positive data from an in vivo study that shows the strong antitumoral efficacy of individual INTASYL pipeline products, including PH-762, PH-790 and PH-804, can be further improved by combining them in a single therapeutic. These data were presented during The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting - Abstract 198: "Combination intratumoral treatment with INTASYL(tm) self-delivering RNAi targeting TIGIT and PD-1/PD-L1 improves tumor control compared to monotherapy in a CT26 model of murine colorectal cancer ".